Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2025-522563-15-00 | Other Identifier | EU CT |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube shaped ducts. Pancreatic cancer often starts in these ducts. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan when given in combination with fluorouracil, folinic acid, and oxaliplatin (FOLFOX) to treat adult participants with pancreatic ductal cancer.
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of pancreatic ductal adenocarcinoma (PDAC). This study will be divided into two phases, with the first phase (Phase 2) treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX. Participants will then be randomized into 3 groups called treatment arms. Two groups will receive telisotuzumab adizutecan with FOLFOX with different optimized doses. One group will receive standard of care (SOC) - fluorouracil, leucovorin, oxaliplatin, and irinotecan. In the second phase (Phase 3), participants will be randomized into 2 arms to receive either the optimal dose of telisotuzumab adizutecan (from the previous phase) with FOLFOLX, or SOC. Approximately 900 participants with PDAC will be enrolled in this study in approximately 200 sites worldwide.
Phase 2 includes a dose escalation stage and a dose optimization stage. In the dose escalation stage, participants will receive escalating doses of Intravenous (IV) telisotuzumab adizutecan + FOLFOX. In the dose optimization stage, participants will receive 1 of 2 doses of IV telisotuzumab adizutecan with FOLFOX or SOC. At the start of Phase 3, participants will receive the optimal dose of IV telisotuzumab adizutecan with FOLFOX or SOC. The study will run for a duration of approximately 6 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ph 2: Dose Escalation Telisotuzumab Adizutecan + FOLFOX | Experimental | Participants will receive Telisotuzumab Adizutecan + fluorouracil, folinic acid, and oxaliplatin (FOLFOX) until doses for optimization are determined, as part of an approximately 2 year study period. |
|
| Ph 2: Dose Optimization Telisotuzumab Adizutecan+FOLFOX Dose A | Experimental | Participants will receive Telisotuzumab Adizutecan+FOLFOX Dose A as part of the approximately 2 year study duration. |
|
| Ph 2: Dose Optimization Telisotuzumab Adizutecan+FOLFOX Dose B | Experimental | Participants will receive Telisotuzumab Adizutecan+FOLFOX Dose B as part of the approximately 2 year study duration. |
|
| Ph 2: Dose Optimization Standard of Care (SOC) mFOLFIRINOX | Active Comparator | Participants will receive SOC (fluorouracil, leucovorin, oxaliplatin, and irinotecan) as part of the approximately 2 year study duration. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Telisotuzumab adizutecan | Drug | Intravenous (IV) Infusion |
|
| Measure | Description | Time Frame |
|---|---|---|
| Phase 2 and Phase 3: Overall Response (OR) Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | OR is defined as participants achieving a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) assessed by BICR per RECIST v1.1. | through study completion, approximately 6 years |
| Phase 3: Overall Survival (OS) | OS is defined as the time from date of randomization to the death from any cause. | through study completion, approximately 6 years |
| Measure | Description | Time Frame |
|---|---|---|
| Phase 2 and Phase 3: Progression-Free Survival (PFS) assessed by BICR per RECIST v1.1 | PFS is defined as the time from the date of randomization or date of first dose of study treatment to the first occurrence of radiographic progression assessed by BICR per RECIST v1.1 or death from any cause, whichever occurs first. | through study completion, approximately 6 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| ABBVIE CALL CENTER | Contact | 844-663-3742 | abbvieclinicaltrials@abbvie.com |
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| City Of Hope - Chicago /ID# 279814 | Recruiting | Zion | Illinois | 60099 | United States | |
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Ph 3: Telisotuzumab Adizutecan RP3D + FOLFOX | Experimental | Participants will receive Telisotuzumab Adizutecan recommended Phase 3 dose (RP3D) + FOLFOX as part of an approximately 2 year study period. |
|
| Ph 3: SOC mFOLFIRINOX | Active Comparator | Participants will receive SOC (fluorouracil, leucovorin, oxaliplatin, and irinotecan) as part of the approximately 2 year study duration. |
|
| Fluorouracil | Drug | IV Infusion |
|
| Folinic acid/ Leucovorina | Drug | IV Infusion |
|
| Oxaliplatin | Drug | IV Infusion |
|
| Irinotecan | Drug | IV Infusion |
|
| Phase 2 and Phase 3: Duration Of Response (DoR) assessed by BICR per RECIST v1.1 | DoR is defined as time from the initial response of Complete Response or Partial Response assessed by BICR per RECIST v1.1 to the first occurrence of radiographic progression assessed by BICR per RECIST v1.1 or death from any cause, whichever occurs first. | through study completion, approximately 6 years |
| Phase 2 and Phase 3: Clinical Benefit (CB) assessed by BICR per RECIST v1.1 | CB is defined as a participant achieving best overall response of confirmed CR or confirmed PR, or SD (with a minimum duration of 24 weeks) assessed by BICR per RECIST v1.1. | through study completion, approximately 6 years |
| Phase 2 : Overall Survival | OS is defined as the time from the date of randomization or date of first dose of study treatment to the event of death from any cause | through study completion, approximately 6 years |
| Phase 3: Change from baseline and time to deterioration in scale of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire - Core 30-item (EORTC QLQ-C30) | The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales, 3 symptom scales, a global health status/QoL scale, and 6 single items. Participants rate items on a 4-point scale ranging from 1 (not at all) to 4 (very much). | through study completion, approximately 6 years |
| Phase 3: Change from baseline and time to deterioration in scale of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire - Pancreatic Cancer Module (EORTC QLQ-PAN26) | The EORTC QLQ-PAN is a PDAC-specific module and consists of 26 questions assessing pancreatic cancer- and treatment-related symptoms and impact, including 7 scales, and 10 single items, All questions employ a one week recall period, and each item is assessed on a Likert scale from 1 (not at all) to 4 (very much). | through study completion, approximately 6 years |
| Phase 3: Change in Selected items of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in patients participating in cancer clinical trials. PRO-CTCAE includes 124 items representing 78 symptomatic toxicities drawn from the Common Terminology Criteria for Adverse Events (CTCAE). PRO-CTCAE items evaluate the symptom attributes of frequency, severity, interference, amount, presence/absence. All questions employ a 7-day recall period and are scored from 0 to 4 (or 0/1 for absent/present). | through study completion, approximately 6 years |
| Phase 3: Change in GP5 item of the Functional Assessment of Cancer Therapy-General (FACT-G) | The FACT GP5 item ("I am bothered by side effects of treatment") is used to assess overall treatment tolerability in patients by assessing the overall side effect impact on patients. This item is rated on a 5- point Likert scale from 0="not at all" to 4="very much." | through study completion, approximately 6 years |
| Phase 3: Change in Selected items of Patient Global Impression of Severity (PGIS) | The PGIS scale asks the participant to assess the severity of their PDAC symptoms over the past 7 days and employs a 5-point response scale ranging from "None" to "Very Severe". | through study completion, approximately 6 years |
| Phase 3: Change in Selected items of Patient Global Impression of Change (PGIC) | The PGIC scale assesses patients' perceptions of change in their PDAC symptoms since the start of treatment in the study and employs a 7-point response scale ranging from "Much Better" to "Much worse". | through study completion, approximately 6 years |
| Phase 3: Change from baseline in European Quality of Life 5 Dimensions (EQ-5D-5L) | The EQ-5D-5L is a generic preference instrument that has been validated in numerous cancer populations. The EQ-5D-5L consists of 2 components: the EQ-5D descriptive system and the EQ VAS. The EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The EQ VAS records the participant's self-rated health on a vertical VAS where 100 represents "The best health you can imagine" and 0 represents "The worst health you can imagine." | through study completion, approximately 6 years |
| Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 279853 |
| Recruiting |
| Grand Rapids |
| Michigan |
| 49503 |
| United States |
| Texas Oncology - Northeast Texas /ID# 280417 | Recruiting | Tyler | Texas | 75702 | United States |
| Virginia Cancer Specialists - Fairfax /ID# 280415 | Recruiting | Fairfax | Virginia | 22031 | United States |
| Tamworth Hospital /ID# 280099 | Not yet recruiting | North Tamworth | New South Wales | 2340 | Australia |
| Prince Of Wales Hospital - Randwick /ID# 280085 | Not yet recruiting | Randwick | New South Wales | 2031 | Australia |
| Monash Health - Monash Medical Centre - Clayton /ID# 280076 | Not yet recruiting | Clayton | Victoria | 3168 | Australia |
| Fiona Stanley Hospital /ID# 280079 | Not yet recruiting | Murdoch | Western Australia | 6150 | Australia |
| The Chaim Sheba Medical Center /ID# 279408 | Recruiting | Ramat Gan | Tel Aviv | 5265601 | Israel |
| Tel Aviv Sourasky Medical Center /ID# 279414 | Recruiting | Tel Aviv | Tel Aviv | 6423906 | Israel |
| Rambam Health Care Campus- Haifa /ID# 279409 | Recruiting | Haifa | 3109601 | Israel |
| Hadassah Medical Center-Hebrew University /ID# 279411 | Recruiting | Jerusalem | 91120 | Israel |
| The Cancer Institute Hospital Of JFCR /ID# 280140 | Recruiting | Koto-ku | Tokyo | 135-8550 | Japan |
| Seoul National University Hospital /ID# 280191 | Recruiting | Seoul | Seoul Teugbyeolsi | 03080 | South Korea |
| Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 279735 | Recruiting | Kaohsiung City | 807 | Taiwan |
| China Medical University Hospital /ID# 279725 | Recruiting | Taichung | 40447 | Taiwan |
| Taipei Veterans General Hospital /ID# 279726 | Recruiting | Taipei | 112 | Taiwan |
| Oxford University Hospital NHS Trust /ID# 279764 | Recruiting | Oxford | Oxfordshire | OX3 7LE | United Kingdom |
| ID | Term |
|---|---|
| D005472 | Fluorouracil |
| D002955 | Leucovorin |
| D000077150 | Oxaliplatin |
| D000077146 | Irinotecan |
| ID | Term |
|---|---|
| D014498 | Uracil |
| D011744 | Pyrimidinones |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D005575 | Formyltetrahydrofolates |
| D013763 | Tetrahydrofolates |
| D005492 | Folic Acid |
| D011622 | Pterins |
| D011621 | Pteridines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D003067 | Coenzymes |
| D045762 | Enzymes and Coenzymes |
| D056831 | Coordination Complexes |
| D009930 | Organic Chemicals |
| D002166 | Camptothecin |
| D000470 | Alkaloids |
Not provided
Not provided